Loss

BIONTECH DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against BioNTech SE and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, March 9, 2024

Investors have until March 12, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until March 12, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Click here to participate in the action.
  • According to the filed complaint, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects.
  • There is no cost or obligation to you.

El Pollo Loco Holdings, Inc. Announces Fourth Quarter 2023 Financial Results

Retrieved on: 
Thursday, March 7, 2024

COSTA MESA, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- El Pollo Loco Holdings, Inc. (Nasdaq: LOCO) today announced financial results for the 13-week period ended December 27, 2023.

Key Points: 
  • COSTA MESA, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- El Pollo Loco Holdings, Inc. (Nasdaq: LOCO) today announced financial results for the 13-week period ended December 27, 2023.
  • Income from operations in the fourth quarter of 2023 was $7.5 million, compared to $9.5 million in the fourth quarter of 2022.
  • General and administrative expenses in the fourth quarter of 2023 was $10.6 million, compared to $9.6 million in the fourth quarter of 2022.
  • The Company will host a conference call to discuss financial results for the fourth quarter of 2023 today at 4:30 PM Eastern Time.

Noodles & Company Announces Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Thursday, March 7, 2024

BROOMFIELD, Colo., March 07, 2024 (GLOBE NEWSWIRE) -- Noodles & Company (Nasdaq: NDLS) today announced financial results for the fourth quarter and fiscal year ended January 2, 2024, and provided a 2024 business outlook.

Key Points: 
  • BROOMFIELD, Colo., March 07, 2024 (GLOBE NEWSWIRE) -- Noodles & Company (Nasdaq: NDLS) today announced financial results for the fourth quarter and fiscal year ended January 2, 2024, and provided a 2024 business outlook.
  • Key highlights for the fourth quarter of 2023 (13 weeks) compared to the fourth quarter of 2022 (14 weeks) include:
    Total revenue decreased 8.9% to $124.3 million from $136.5 million.
  • Adjusting for the impact of the 53rd week in the fourth quarter of 2022, total revenue decreased $3.1 million in the fourth quarter of 2023, or 2.4%.
  • Noodles & Company will host a conference call to discuss its fourth quarter and fiscal year 2023 financial results on Thursday, March 7, 2024 at 4:30 p.m. EST.

HCI Group Reports Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Thursday, March 7, 2024

TAMPA, Fla., March 07, 2024 (GLOBE NEWSWIRE) -- HCI Group, Inc. (NYSE:HCI), a holding company with operations in homeowners insurance, information technology services, real estate, and reinsurance, reported pre-tax income of $54.2 million and net income of $40.9 million, or $3.40 diluted earnings per share, in the fourth quarter of 2023, compared with net income of $2.7 million, or $0.18 diluted earnings per share, in the fourth quarter of 2022.

Key Points: 
  • Premiums ceded for reinsurance in the fourth quarter decreased to $66.6 million from $77.0 million in the fourth quarter of 2022.
  • Premiums ceded represented 30.9% of gross premiums earned in the fourth quarter of 2023 compared with 42.1% in the fourth quarter of 2022.
  • Net investment income in the fourth quarter was $10.3 million compared with $7.4 million in the fourth quarter of 2022.
  • Losses and loss adjustment expenses in the fourth quarter decreased to $65.4 million from $72.1 million in the fourth quarter of 2022.

Aquestive Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, March 5, 2024

Aquestive received positive feedback in October 2023 from the U.S. Food and Drug Administration (FDA) on the Company's pivotal Phase 3 Pharmacokinetic (PK) clinical protocol for Anaphylm.

Key Points: 
  • Aquestive received positive feedback in October 2023 from the U.S. Food and Drug Administration (FDA) on the Company's pivotal Phase 3 Pharmacokinetic (PK) clinical protocol for Anaphylm.
  • Aquestive commenced dosing in December 2023 in the Phase 3 pivotal PK clinical study of Anaphylm.
  • Non-GAAP adjusted EBITDA loss was $2.8 million in the fourth quarter 2023, compared to a $9.6 million loss in the fourth quarter 2022.
  • During the fourth quarter 2023, the Company accessed capital net proceeds of $3.7 million under its "At-the-Market" (ATM) facility.

Levi & Korsinsky Notifies Shareholders of Maplebear Inc. d/b/a Instacart(CART) of a Class Action Lawsuit and an Upcoming Deadline

Retrieved on: 
Tuesday, March 5, 2024

NEW YORK, March 05, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Maplebear Inc. d/b/a Instacart ("Maplebear" or the "Company") (NASDAQ: CART) of a class action securities lawsuit.

Key Points: 
  • NEW YORK, March 05, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Maplebear Inc. d/b/a Instacart ("Maplebear" or the "Company") (NASDAQ: CART) of a class action securities lawsuit.
  • CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Maplebear investors who were adversely affected by alleged securities fraud.
  • WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases.
  • For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

Levi & Korsinsky Notifies Shareholders of AlloVir, Inc. (ALVR) of a Class Action Lawsuit and an Upcoming Deadline

Retrieved on: 
Tuesday, March 5, 2024

NEW YORK, March 05, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in AlloVir, Inc. ("AlloVir" or the "Company") (NASDAQ: ALVR) of a class action securities lawsuit.

Key Points: 
  • NEW YORK, March 05, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in AlloVir, Inc. ("AlloVir" or the "Company") (NASDAQ: ALVR) of a class action securities lawsuit.
  • Follow the link below to get more information and be contacted by a member of our team:
    ALVR investors may also contact Joseph E. Levi, Esq.
  • WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases.
  • For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

ALVR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that AlloVir Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on: 
Tuesday, March 5, 2024

Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/ALVR .

Key Points: 
  • Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/ALVR .
  • The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the AlloVir's business, operations, and prospects.
  • or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

Class Action Lawsuit Filed on Behalf of Ventyx Biosciences, Inc. (VTYX) Investors – Nationally Ranked Investors’ Rights Firm Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm

Retrieved on: 
Monday, March 4, 2024

ATLANTA, March 04, 2024 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Ventyx Biosciences, Inc. (“Ventyx” or the “Company”) (NASDAQ: VTYX).

Key Points: 
  • ATLANTA, March 04, 2024 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Ventyx Biosciences, Inc. (“Ventyx” or the “Company”) (NASDAQ: VTYX).
  • Holzer & Holzer, LLC, an ISS top rated securities litigation law firm for 2021 and 2022, dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation.
  • More information about the firm is available through its website, www.holzerlaw.com , and upon request from the firm.
  • Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey Holzer is the attorney responsible for its content.

Pimco Dynamic Income Strategy Fund Declares Common Share Distributions

Retrieved on: 
Friday, March 1, 2024

There can be no assurance that the Fund or any investment strategy will achieve its investment objectives or structure its investment portfolio as anticipated.

Key Points: 
  • There can be no assurance that the Fund or any investment strategy will achieve its investment objectives or structure its investment portfolio as anticipated.
  • Any recharacterization of payments made or received by the Fund pursuant to derivatives potentially could affect the amount, timing or character of Fund distributions.
  • If you sell your common shares of the Fund, the price received may be more or less than your original investment.
  • As a result, during the Wind-Down Period, the Fund’s distributions may decrease, and such distributions may include a return of capital.